|Bid||8.03 x 4000|
|Ask||8.10 x 900|
|Day's range||7.88 - 8.31|
|52-week range||3.50 - 24.90|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||13.40|
Shares of Vaxart (NASDAQ: VXRT) jumped 31.2% through the first half of 2021, according to data from S&P Global Market Intelligence. Over the period, the stock rose as much as 300% and fell as low as 11% below where it began the year. Investors began the year with a positive outlook for the company's proposed tablet-based COVID-19 vaccine, VXA-CoV2-1.
The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.
Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await. The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ: VXRT).